Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 4/20 | 0.35 |
| ▸ | THRB | P10828 | 4/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7249537 | 0.87 | NR3C1 (0.70) | NR3C1THRATHRB | |
| SCHEMBL7250252 | 0.85 | NR3C1 (0.58) | NR3C1THRATHRB | |
| SCHEMBL7251075 | 0.84 | NR3C1 (0.46) | NR3C1LPAR1TOP2ATOP2B | |
| SCHEMBL7052439 | 0.83 | NR3C1 (0.75) | NR3C1LPAR1AKR1C3AKR1C2PTGS1 | |
| SCHEMBL7250256 | 0.81 | NR3C1 (0.43) | NR3C1LPAR1THRATHRBTOP2A | |
| SCHEMBL7250347 | 0.80 | NR3C1 (0.46) | NR3C1LPAR1TOP2ATOP2B | |
| SCHEMBL7250267 | 0.78 | NR3C1 (0.61) | NR3C1THRATHRB | |
| SCHEMBL7250938 | 0.77 | NR3C1 (0.57) | NR3C1THRATHRB | |
| SCHEMBL7250359 | 0.77 | NR3C1 (0.70) | NR3C1THRATHRB | |
| SCHEMBL7255589 | 0.77 | NR3C1 (0.57) | NR3C1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166725-A1 | Compounds active at the glucocorticoid receptor | KARO BIO AB (SE) | 2003-09-04 | — | — | US | claimed |
| EP-1265839-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2002-12-18 | — | — | EP | claimed |
| WO-2001047859-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2001-07-05 | — | — | WO | claimed |
| US-20030166725-A1 | Compounds active at the glucocorticoid receptor | KARO BIO AB (SE) | 2003-09-04 | — | — | US | disclosed |
| EP-1265839-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001047859-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166725-A1 | Compounds active at the glucocorticoid receptor | NR3C1, NR3C2, GPR119 | NR3C1 1/4885LPAR1 306/4885AKR1C3 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.